Been there, not done that--melanoma in the age of molecular therapy.

  • Ernstoff M
  • 43


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


In 1976, the detection of estrogen-receptor expression in melanomas ushered in the era of targeted therapy in melanoma, although we did not use that term back then.(1) In 1992, Cocconi et al. found that dacarbazine plus tamoxifen provided a higher response rate and longer survival than dacarbazine, but only in women.(2) Subsequently, whether melanoma cells express estrogen receptors was questioned, and the efficacy of tamoxifen could not be confirmed. Since then, the drug has not been used to treat melanoma. However, molecular analysis of tumors has revealed specific growth-promoting pathways in human cancers that have become targets for therapy. BRAF . . .

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Marc S Ernstoff

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free